Biovie (BIVI) Research & Development (2013 - 2026)
Biovie (BIVI) posted Research & Development of $3.2 million for Q1 2026, down 25.59% sequentially from $4.3 million in Q4 2025, and up 136.21% YoY from $1.3 million in Q1 2025.
Biovie (BIVI) Research & Development (2013 - 2026) Analysis & Trends
Biovie has reported Research & Development for 13 years, with the latest figure at $3.2 million in Q1 2026.
- Quarterly Research & Development rose 136.21% year-over-year to $3.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.6 million (up 14.99% YoY) and the FY2025 annual result came in at $9.3 million, down 59.88% from the prior year.
- Research & Development slipped to $3.2 million in Q1 2026 per BIVI's latest filing, from $4.3 million in the prior quarter.
- Over five years, Research & Development peaked at $11.2 million in Q1 2023 and troughed at $1.2 million in Q2 2025.
- A 5-year average of $5.0 million and a median of $4.7 million in 2024 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2024: Research & Development jumped 1018.43% in 2022, then slumped 77.58% in 2024.
- Over 5 years, Research & Development stood at $7.0 million in 2022, then retreated by 8.0% to $6.5 million in 2023, then decreased by 27.29% to $4.7 million in 2024, then dropped by 9.25% to $4.3 million in 2025, then retreated by 25.59% to $3.2 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $3.2 million, $4.3 million, and $2.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.76 Bn | 131.91 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.51 Bn | 78.51 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 65.74 Bn | 60.56 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 59.39 Bn | 54.26 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 42.24 Bn | 37.15 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.78 Bn | 28.47 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.65 Bn | 10.26 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.22 Bn | 26.39 Bn | - | 97.90 Mn |
| 10 | Biovie | 14.17 Mn | 14.17 Mn | - | 3.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.58 Mn |
| Mar 31, 2026 | 3.18 Mn |
| Dec 31, 2025 | 4.27 Mn |
| Sep 30, 2025 | 2.94 Mn |
| Jun 30, 2025 | 1.22 Mn |
| Mar 31, 2025 | 1.34 Mn |
| Dec 31, 2024 | 4.70 Mn |
| Sep 30, 2024 | 1.99 Mn |
| Jun 30, 2024 | 2.05 Mn |
| Mar 31, 2024 | 5.70 Mn |
| Dec 31, 2023 | 6.47 Mn |
| Sep 30, 2023 | 8.88 Mn |
| Jun 30, 2023 | 8.30 Mn |
| Mar 31, 2023 | 11.20 Mn |
| Dec 31, 2022 | 7.03 Mn |
| Sep 30, 2022 | 6.77 Mn |
| Jun 30, 2022 | 5.87 Mn |
| Mar 31, 2022 | 3.58 Mn |
| Dec 31, 2021 | 4.71 Mn |
| Sep 30, 2021 | 3.09 Mn |